Chondrostem / CELL Technologies, Canadian Centre For Regenerative Therapy - LARVOL DELTA

CELL Announces The Award of a No Objection Letter from Health Canada And The Approval of The First Ever Pivotal Stem Cell Clinical Program for Pain in The World (PRNewswire) - "CELL Technologies Inc. is pleased to announce the award of a No Objection Letter (NOL) from Health Canada to launch the first ever pivotal stem cell program in pain and Osteoarthritis in the world....The program now allows patients with pain conditions to enroll in evidence-based and regulatory validated stem cell treatment across all Canada....Based on the breakthrough data and the positive regulatory approval, CELL is now preparing to file with the FDA to get a similar approval in the US."

New trial • CNS Disorders • Osteoarthritis • Pain

CELL Announces The Submission of Its Stem Cell Clinical Data in Pain And Arthritis to Health Canada (Canada Newswire) - "On the heel of the regulatory meeting with Health Canada on March 31st 2023, CELL Technologies Inc. announces the submission of the clinical data of its stem cell program in pain for Health Canada approval. CELL is aiming to become the first regulatory approved stem cell provider in North America. CELL submitted clinical data of 3 studies in Arthritis, degenerative disc disease and back pain. The program will allow patients with pain conditions to access evidence-based and regulatory approved stem cell procedures across all Canada."

Canadian regulatory • Back Pain • CNS Disorders • Osteoarthritis • Pain